Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
Journal Title
Clinical and Translational Radiation Oncology
Publication Type
Research article
Abstract
PURPOSE /OBJECTIVES MATERIALS/METHODS: The National Cancer Database (NCDB) was queried (2004-2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate overall survival (OS). Univariable (UVA) and multivariable (MVA) analysis were conducted using cox proportional hazard models to determine prognostic factors for OS. RESULTS: A total of 344 patients with median age 77 (IQR 70-85) were included in this study. Median BED(3) was 180 Gy (IQR 126.03-233.97). Median OS was 90 months in the highest quartile compared to 36-52 months in the lower three quartiles (p < 0.01). On UVA, the highest BED(3) quartile was a positive prognostic factor (HR 0.67, p < 0.01 CI 0.51-0.91) while age, tumor size, T-stage, metastasis, renal pelvis location, and transitional cell histology were negative factors. On MVA, the highest BED(3) quartile was remained significant (HR 0.69, p = 0.02; CI 0.49-0.95) as a positive factor, while age, metastasis were negative factors. CONCLUSION: Higher BED may be associated with improved OS. Prospective investigation is needed to clearly define optimal BED for SBRT used to treat RCC.
Publisher
Elsevier
Department(s)
Radiation Oncology
PubMed ID
36935857
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-06-15 07:24:50
Last Modified: 2024-07-30 02:07:28

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙